
Merck & Co Inc
NYSE:MRK

Intrinsic Value
The intrinsic value of one
MRK
stock under the Base Case scenario is
137.5
USD.
Compared to the current market price of 79.12 USD,
Merck & Co Inc
is
Undervalued by 42%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Merck & Co Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Merck & Co Inc
Balance Sheet Decomposition
Merck & Co Inc
Current Assets | 38.8B |
Cash & Short-Term Investments | 13.7B |
Receivables | 11.1B |
Other Current Assets | 14B |
Non-Current Assets | 78.3B |
Long-Term Investments | 1.6B |
PP&E | 23.8B |
Intangibles | 38B |
Other Non-Current Assets | 14.9B |
Free Cash Flow Analysis
Merck & Co Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Merck & Co Inc
Revenue
|
63.9B
USD
|
Cost of Revenue
|
-13.3B
USD
|
Gross Profit
|
50.6B
USD
|
Operating Expenses
|
-28.3B
USD
|
Operating Income
|
22.3B
USD
|
Other Expenses
|
-4.8B
USD
|
Net Income
|
17.4B
USD
|
MRK Profitability Score
Profitability Due Diligence
Merck & Co Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Score
Merck & Co Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
MRK Solvency Score
Solvency Due Diligence
Merck & Co Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Score
Merck & Co Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRK Price Targets Summary
Merck & Co Inc
According to Wall Street analysts, the average 1-year price target for
MRK
is 108.01 USD
with a low forecast of 82.82 USD and a high forecast of 153.3 USD.
Dividends
Current shareholder yield for MRK is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
MRK
stock under the Base Case scenario is
137.5
USD.
Compared to the current market price of 79.12 USD,
Merck & Co Inc
is
Undervalued by 42%.